These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37414252)

  • 1. Radiosensitizing oxygenation changes in murine tumors treated with VEGF-ablation therapy are measurable using oxygen enhanced-MRI (OE-MRI).
    Baker JHE; Moosvi F; Kyle AH; Püspöky Banáth J; Saatchi K; Häfeli UO; Reinsberg SA; Minchinton AI
    Radiother Oncol; 2023 Oct; 187():109795. PubMed ID: 37414252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fast and sensitive dynamic oxygen-enhanced MRI with a cycling gas challenge and independent component analysis.
    Moosvi F; Baker JHE; Yung A; Kozlowski P; Minchinton AI; Reinsberg SA
    Magn Reson Med; 2019 Apr; 81(4):2514-2525. PubMed ID: 30368892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF).
    Baker JH; McPhee KC; Moosvi F; Saatchi K; Häfeli UO; Minchinton AI; Reinsberg SA
    Contrast Media Mol Imaging; 2016; 11(1):77-88. PubMed ID: 26268906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
    Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
    Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma.
    Linnik IV; Scott ML; Holliday KF; Woodhouse N; Waterton JC; O'Connor JP; Barjat H; Liess C; Ulloa J; Young H; Dive C; Hodgkinson CL; Ward T; Roberts D; Mills SJ; Thompson G; Buonaccorsi GA; Cheung S; Jackson A; Naish JH; Parker GJ
    Magn Reson Med; 2014 May; 71(5):1854-62. PubMed ID: 23798369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data-driven mapping of hypoxia-related tumor heterogeneity using DCE-MRI and OE-MRI.
    Featherstone AK; O'Connor JPB; Little RA; Watson Y; Cheung S; Babur M; Williams KJ; Matthews JC; Parker GJM
    Magn Reson Med; 2018 Apr; 79(4):2236-2245. PubMed ID: 28856728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of Oxygen Enhanced Magnetic Resonance Imaging (OE-MRI) and a Pilot Genomic Study of Hypoxia in Bladder Cancer Xenografts.
    Shabbir R; Telfer BA; Dickie B; Reardon M; Babur M; Williams K; West CML; Choudhury A; Smith TAD
    Cancer Genomics Proteomics; 2024; 21(4):380-387. PubMed ID: 38944425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multimodal Molecular Imaging Study Evaluates Pharmacological Alteration of the Tumor Microenvironment to Improve Radiation Response.
    Takakusagi Y; Naz S; Takakusagi K; Ishima M; Murata H; Ohta K; Miura M; Sugawara F; Sakaguchi K; Kishimoto S; Munasinghe JP; Mitchell JB; Krishna MC
    Cancer Res; 2018 Dec; 78(24):6828-6837. PubMed ID: 30301838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model.
    Ceelen W; Smeets P; Backes W; Van Damme N; Boterberg T; Demetter P; Bouckenooghe I; De Visschere M; Peeters M; Pattyn P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1188-96. PubMed ID: 16457965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia imaging in brain tumors.
    Yetkin FZ; Mendelsohn D
    Neuroimaging Clin N Am; 2002 Nov; 12(4):537-52. PubMed ID: 12687910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaussian mixture model-based classification of dynamic contrast enhanced MRI data for identifying diverse tumor microenvironments: preliminary results.
    Han SH; Ackerstaff E; Stoyanova R; Carlin S; Huang W; Koutcher JA; Kim JK; Cho G; Jang G; Cho H
    NMR Biomed; 2013 May; 26(5):519-32. PubMed ID: 23440683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
    NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Oxygen-Enhanced MRI and Perfusion Imaging Detect Hypoxia Modification from Banoxantrone and Atovaquone and Track Their Differential Mechanisms of Action.
    O'Connor JPB; Tessyman V; Little RA; Babur M; Forster D; Latif A; Cheung S; Lipowska-Bhalla G; Higgins GS; Asselin MC; Parker GJM; Williams KJ
    Cancer Res Commun; 2024 Oct; 4(10):2565-2574. PubMed ID: 39240065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DCE-MRI and Quantitative Histology Reveal Enhanced Vessel Maturation but Impaired Perfusion and Increased Hypoxia in Bevacizumab-Treated Cervical Carcinoma.
    Hauge A; Gaustad JV; Huang R; Simonsen TG; Wegner CS; Andersen LMK; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):666-676. PubMed ID: 30858145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.
    Malamas AS; Jin E; Zhang Q; Haaga J; Lu ZR
    Pharm Res; 2015 Sep; 32(9):3029-43. PubMed ID: 25840948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring Combretastatin A4-induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE-MRI.
    Colliez F; Fruytier AC; Magat J; Neveu MA; Cani PD; Gallez B; Jordan BF
    Magn Reson Med; 2016 Feb; 75(2):866-72. PubMed ID: 25765253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
    Hoffmann E; Gerwing M; Krähling T; Hansen U; Kronenberg K; Masthoff M; Geyer C; Höltke C; Wachsmuth L; Schinner R; Hoerr V; Heindel W; Karst U; Eisenblätter M; Maus B; Helfen A; Faber C; Wildgruber M
    Breast Cancer Res; 2023 May; 25(1):56. PubMed ID: 37221619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DCE-MRI of patient-derived xenograft models of uterine cervix carcinoma: associations with parameters of the tumor microenvironment.
    Hauge A; Wegner CS; Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK
    J Transl Med; 2017 Nov; 15(1):225. PubMed ID: 29100521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.
    Jordan BF; Runquist M; Raghunand N; Baker A; Williams R; Kirkpatrick L; Powis G; Gillies RJ
    Neoplasia; 2005 May; 7(5):475-85. PubMed ID: 15967100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.